Arcus Biosciences Inc
NYSE:RCUS
Arcus Biosciences Inc
Total Liabilities
Arcus Biosciences Inc
Total Liabilities Peer Comparison
Competitive Total Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Arcus Biosciences Inc
NYSE:RCUS
|
Total Liabilities
$586m
|
CAGR 3-Years
29%
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities
$140.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
19%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities
$38.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
10%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities
$88B
|
CAGR 3-Years
18%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities
$5.4B
|
CAGR 3-Years
20%
|
CAGR 5-Years
24%
|
CAGR 10-Years
19%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities
$7.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
17%
|
CAGR 10-Years
22%
|
See Also
What is Arcus Biosciences Inc's Total Liabilities?
Total Liabilities
586m
USD
Based on the financial report for Mar 31, 2024, Arcus Biosciences Inc's Total Liabilities amounts to 586m USD.
What is Arcus Biosciences Inc's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
74%
Over the last year, the Total Liabilities growth was -10%. The average annual Total Liabilities growth rates for Arcus Biosciences Inc have been 29% over the past three years , 74% over the past five years .